I understand now! I agree that IPIX is very well positioned and they are doing exactly what they told us they would do....get the indications to the mid-stage clinical trial level and then seek partnerships/licensing/buyouts. I believe this is why additional trials have not been specifically identified in recent PRs and are only discussed in concept for the future when partners are on board. I look forward to upcoming P results and the potential that the 505(2)b designation can provide.....if results are as hoped, this is going to get very interesting!